

EBViously Announces Publication of International Patent for Novel Epstein–Barr Virus (EBV) Vaccine and Antibody Platform

Munich, Germany — January 20, 2026 — EBViously, a biotechnology company pioneering next-generation virus-like particle (VLP) vaccines, wants to announce the publication of the international patent application **WO2025209940**, titled “*EBV Vaccine and Antibodies*”, filed by Helmholtz Munich. The patent details novel vaccine compositions and antibody candidates aimed at preventing and treating Epstein–Barr Virus (EBV) infections and EBV-associated diseases.

EBV infects over 90% of the global population and is linked to a range of serious conditions, including infectious mononucleosis, multiple sclerosis, and several cancers—underscoring a significant unmet medical need. The newly published patent outlines innovations in antigen design and antibody engineering intended to elicit strong, durable immune responses.

“This patent application represents a major milestone for EBViously and validates the uniqueness of our scientific platform,” said **Sebastian Goy**, CEO of EBViously. “Our lead vaccine candidate, **EBV-001**, is currently the only one in development that incorporates this newly patented viral antigen.”

Prof. Hammerschmidt, inventor of EBV-001, added: “Our EBV vaccine program is designed to close a long-standing gap in the prevention and treatment of EBV-related diseases. The patent claims strengthen the foundation for developing our clinically relevant and potent vaccine candidate EBV-001. We identified robust antibody responses to EBV-001 in immunized rodents, which target a largely overlooked EBV glycoprotein. These antibodies inhibit epithelial cell infection and, notably, are surprisingly prevalent in sera from EBV controllers. Given its functional role and strong immunogenicity in humans, this protein clearly represents a promising antigen candidate for inclusion in multivalent EBV vaccines.”

The GMP production of EBV-001 will start in Q1 2026 and first-in-human trials can start as early as second half of 2026. EBViously is actively exploring strategic collaborations to accelerate clinical translation.

About EBViously

EBViously is a spin-off from **Helmholtz Munich**, focused on developing next-generation vaccines using virus-like particle (VLP) platforms. The company brings together leading experts in Epstein–Barr virus research. Helmholtz Munich has secured over **€12 million** in funding from the **German Center for Infection Research (DZIF)** and the **Helmholtz Validation Fund (HVF)**. GMP manufacturing of the clinical vaccine candidate EBV-001 is set to begin in **Q1 2026**. EBViously has exclusively secured the relevant patent portfolio from Helmholtz Munich for further development and commercialization of the EBV vaccine program.

About Helmholtz Munich

Helmholtz Munich is a leading biomedical research center. Its mission is to develop breakthrough solutions for better health in a rapidly changing world. Interdisciplinary research teams focus on environmentally triggered diseases, especially the therapy and prevention of

diabetes, obesity, allergies, and chronic lung diseases. With the power of artificial intelligence and bioengineering, researchers accelerate the translation to patients. Helmholtz Munich has more than 2,550 employees and is headquartered in Munich/Neuherberg. It is a member of the Helmholtz Association, with more than 46,000 employees and 18 research centers the largest scientific organization in Germany. More about Helmholtz Munich (Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH): www.helmholtz-munich.de/en

For more information, please contact:

Sebastian Goy

CEO

info@EBViously.com | www.ebviously.com